Abstract 1453P
Background
Immune checkpoint inhibitors (ICIs) have revolutionized lung cancer (LC) treatment. This study aims to describe the trends of ICI in LC treatment.
Methods
We evaluated treatment regimens and clinical outcomes in the use of ICIs for LC in the Netherlands from 2016-2020 using data from the Netherlands Cancer Registry (NCR) on first-line treatments, and performed a secondary analysis using a local cohort within the University Medical Center Groningen (UMCG) containing all-line treatments. Between 2016-2018, the NCR contained mostly data from patients treated in randomized controlled trials (RCTs) as clinical guidelines advised ICIs only in later treatment lines, whilst NCR data from 2018-2020 and from the UMCG from 2016-2020 were mainly collected outside RCTs. Descriptive statistics and annual percentage change (APC) were used to evaluate changes over time. Also, a survival analysis was performed.
Results
The proportion of first-line ICIs in LC treatment increased from 1.1% in 2016 to 54.9% in 2020 in the Netherlands (6816 patients in total, APC=14.5%, p=0.002). In the UMCG, increases were observed in the proportion of any-line ICI-chemotherapy combination (APC=12.4%, p=0.049), patients surviving ≥1 year (APC=5.8%, p<0.001), and partial response as best overall treatment response (APC=9%, p=0.049), whilst NCR data showed no significant changes over the years. NCR median overall survival (OS) was higher in the period 2016-2018 compared to 2019-2020 (83.4 vs 72.7 weeks, p=<0.001), whilst in the UMCG, 2016-2018 showed a lower median OS compared to 2019-2020 (39.3 [95%CI 32.9-48.6] vs 72.4 weeks [95%CI 52.7-87.4]).
Conclusions
The use of ICIs for LC treatment in the Netherlands increased over the years. Survival data showed better response in the use of ICI as any-line treatment in the UMCG from 2019-2020, contrary to data from patients in the NCR. An explanation for this is the inclusion of mainly RCT patients in the NCR data during the early years of ICI use and the recent shift from second to first-line treatment. As new ICI based drugs emerge, updated analyses will be needed using real-world data to evaluate the real benefits of these newly developed treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Mexico’s National Council of Science and Technology (CONACYT) [Grant No. 1074186] European Union’s Horizon 2020 research and innovation program [grant number 875171].
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1443P - Patient-reported outcomes (PROs) with cemiplimab plus chemotherapy (CEMI + CHEMO) for first-line treatment of advanced non-small cell lung cancer (aNSCLC): PD-L1 level subgroups in EMPOWER-Lung 3
Presenter: Miranda Gogishvili
Session: Poster session 20
1444P - Sintilimab with two cycles nab-paclitaxel / platinum as first line therapy for advanced squamous non-small-cell lung cancer: The final analysis and biomarker results
Presenter: Huijuan Wang
Session: Poster session 20
1445P - A randomized phase III trial on Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN), results of the interim analysis
Presenter: Ilias Houda
Session: Poster session 20
1447P - IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Mauricio Burotto
Session: Poster session 20
1449P - The preliminary data from a single-arm, open-label, multicenter phase II clinical trial: KN046 combined with axitinib as first-line (1L) treatment for NSCLC
Presenter: Yuanyuan Zhao
Session: Poster session 20
1450P - Addition of bevacizumab to first-line chemoimmunotherapy in NSCLC with liver metastases
Presenter: Matthieu Roulleaux Dugage
Session: Poster session 20
1451P - Identifying long-term responders to immune checkpoint blockade: Potential utility of serum proteomic profiling in metastatic non-small cell lung cancer
Presenter: Rafael Bach Mora
Session: Poster session 20